Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

O. Mosenzon, A. Alguwaihes, JLA. Leon, F. Bayram, P. Darmon, TME. Davis, G. Dieuzeide, KT. Eriksen, T. Hong, MS. Kaltoft, C. Lengyel, NA. Rhee, GT. Russo, S. Shirabe, K. Urbancova, S. Vencio, CAPTURE Study Investigators

. 2021 ; 20 (1) : 154. [pub] 20210727

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012346

BACKGROUND: There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and its management in adults with T2D across 13 countries from five continents. Additional objectives were to further characterize the study sample regarding demographics, clinical parameters and medication usage, with particular reference to blood glucose-lowering agents (GLAs: glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) with demonstrated cardiovascular benefit in randomized intervention trials. METHODS: Data were collected from adults with T2D managed in primary or specialist care in Australia, China, Japan, Czech Republic, France, Hungary, Italy, Argentina, Brazil, Mexico, Israel, Kingdom of Saudi Arabia, and Turkey in 2019, using standardized methodology. CVD prevalence, weighted by diabetes prevalence in each country, was estimated for the overall CAPTURE sample and participating countries. Country-specific odds ratios for CVD prevalence were further adjusted for relevant demographic and clinical parameters. RESULTS: The overall CAPTURE sample included 9823 adults with T2D (n = 4502 from primary care; n = 5321 from specialist care). The overall CAPTURE sample had median (interquartile range) diabetes duration 10.7 years (5.6-17.9 years) and glycated hemoglobin 7.3% (6.6-8.4%) [56 mmol/mol (49-68 mmol/mol)]. Overall weighted CVD and atherosclerotic CVD prevalence estimates were 34.8% (95% confidence interval [CI] 32.7-36.8) and 31.8% (95% CI 29.7-33.8%), respectively. Age, gender, and clinical parameters accounted for some of the between-country variation in CVD prevalence. GLAs with demonstrated cardiovascular benefit were used by 21.9% of participants, which was similar in participants with and without CVD: 21.5% and 22.2%, respectively. CONCLUSIONS: In 2019, approximately one in three adults with T2D in CAPTURE had diagnosed CVD. The low use of GLAs with demonstrated cardiovascular benefit even in participants with established CVD suggested that most were not managed according to contemporary diabetes and cardiology guidelines. Study registration NCT03786406 (registered on December 20, 2018), NCT03811288 (registered on January 18, 2019).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012346
003      
CZ-PrNML
005      
20250505100807.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12933-021-01344-0 $2 doi
035    __
$a (PubMed)34315481
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Mosenzon, Ofri $u Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Hadassah Hebrew University Hospital, PO Box 12000, 91120, Jerusalem, Israel. ofrim@hadassah.org.il $1 https://orcid.org/0000000257027584
245    10
$a CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries / $c O. Mosenzon, A. Alguwaihes, JLA. Leon, F. Bayram, P. Darmon, TME. Davis, G. Dieuzeide, KT. Eriksen, T. Hong, MS. Kaltoft, C. Lengyel, NA. Rhee, GT. Russo, S. Shirabe, K. Urbancova, S. Vencio, CAPTURE Study Investigators
520    9_
$a BACKGROUND: There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and its management in adults with T2D across 13 countries from five continents. Additional objectives were to further characterize the study sample regarding demographics, clinical parameters and medication usage, with particular reference to blood glucose-lowering agents (GLAs: glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) with demonstrated cardiovascular benefit in randomized intervention trials. METHODS: Data were collected from adults with T2D managed in primary or specialist care in Australia, China, Japan, Czech Republic, France, Hungary, Italy, Argentina, Brazil, Mexico, Israel, Kingdom of Saudi Arabia, and Turkey in 2019, using standardized methodology. CVD prevalence, weighted by diabetes prevalence in each country, was estimated for the overall CAPTURE sample and participating countries. Country-specific odds ratios for CVD prevalence were further adjusted for relevant demographic and clinical parameters. RESULTS: The overall CAPTURE sample included 9823 adults with T2D (n = 4502 from primary care; n = 5321 from specialist care). The overall CAPTURE sample had median (interquartile range) diabetes duration 10.7 years (5.6-17.9 years) and glycated hemoglobin 7.3% (6.6-8.4%) [56 mmol/mol (49-68 mmol/mol)]. Overall weighted CVD and atherosclerotic CVD prevalence estimates were 34.8% (95% confidence interval [CI] 32.7-36.8) and 31.8% (95% CI 29.7-33.8%), respectively. Age, gender, and clinical parameters accounted for some of the between-country variation in CVD prevalence. GLAs with demonstrated cardiovascular benefit were used by 21.9% of participants, which was similar in participants with and without CVD: 21.5% and 22.2%, respectively. CONCLUSIONS: In 2019, approximately one in three adults with T2D in CAPTURE had diagnosed CVD. The low use of GLAs with demonstrated cardiovascular benefit even in participants with established CVD suggested that most were not managed according to contemporary diabetes and cardiology guidelines. Study registration NCT03786406 (registered on December 20, 2018), NCT03811288 (registered on January 18, 2019).
650    _2
$a senioři $7 D000368
650    _2
$a kardiovaskulární nemoci $x diagnóza $x epidemiologie $x prevence a kontrola $7 D002318
650    _2
$a průřezové studie $7 D003430
650    _2
$a diabetes mellitus 2. typu $x diagnóza $x farmakoterapie $x epidemiologie $7 D003924
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x terapeutické užití $7 D007004
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prevalence $7 D015995
650    _2
$a prognóza $7 D011379
650    _2
$a ochranné faktory $7 D065840
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Alguwaihes, Abdullah $u King Saud University, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia
700    1_
$a Leon, Jose Luis Arenas $u Centro de Atención E Investigación Cardiovascular del Potosí, San Luis Potosí, Mexico
700    1_
$a Bayram, Fahri $u Department of Endocrinology and Metabolism, Faculty of Medicine, Erciyes University, Kayseri, Turkey
700    1_
$a Darmon, Patrice $u Aix Marseille University, INSERM, INRA, C2VN, Marseille, France
700    1_
$a Davis, Timothy M E $u Medical School, University of Western Australia, Fremantle Hospital, Fremantle, Australia
700    1_
$a Dieuzeide, Guillermo $u Centro de Atención Integral en Diabetes, Endocrinología Y Metabolismo, Chacabuco, Buenos Aires, Argentina
700    1_
$a Eriksen, Kirsten T $u Novo Nordisk A/S, Søborg, Denmark
700    1_
$a Hong, Tianpei $u Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China
700    1_
$a Kaltoft, Margit S $u Novo Nordisk A/S, Søborg, Denmark
700    1_
$a Lengyel, Csaba $u University of Szeged, Szeged, Hungary
700    1_
$a Rhee, Nicolai A $u Novo Nordisk Health Care AG, Zurich, Switzerland
700    1_
$a Russo, Giuseppina T $u Department of Clinical and Experimental Medicine, Policlinico Universitario, University of Messina, Messina, Italy
700    1_
$a Shirabe, Shinichiro $u H. E. C Science Clinic, Yokohama, Japan
700    1_
$a Cíglová Urbancová Kateřina $u Diabetologická Interní Ambulance S.R.O., Ostrava, Czech Republic $7 xx0331935
700    1_
$a Vencio, Sergio $u Instituto de Ciencias Farmaceuticas, Goiânia, Goiás, Brazil
710    2_
$a CAPTURE Study Investigators
773    0_
$w MED00008211 $t Cardiovascular diabetology $x 1475-2840 $g Roč. 20, č. 1 (2021), s. 154
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34315481 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20250505100808 $b ABA008
999    __
$a ok $b bmc $g 1789790 $s 1163547
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 20 $c 1 $d 154 $e 20210727 $i 1475-2840 $m Cardiovascular diabetology $n Cardiovasc Diabetol $x MED00008211
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace